|
|
Article: Unfavorable Tier Placement Makes Safer Insomnia Drug, Takeda's Rozerem, Less Accessible to Patients.
- Article from:
- PR Newswire
- Article date:
- October 16, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
HMOs' Tier Assignment of Rozerem and Lunesta Ensures Ambien's Status as Lead Agent, According to a New Report from Decision Resources
WALTHAM, Mass., Oct. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite a benign safety profile, Takeda's Rozerem (ramelteon), the first unscheduled agent approved for treating insomnia, faces enormous hurdles -- from unfavorable formulary positioning to primary care physicians' concerns about its onset of action and ability to maintain sleep.
"Although a high percentage of primary care physicians select Rozerem as a ...